AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.



Company founding

PMic 06.jpg

When argenx sought a worldwide expert in growth factor biology, they turned to Professor Paolo Michieli, an academic investigator leading a Translational Medicine team at the University of Torino, Italy. During his long-lasting collaboration with argenx, Paolo intuited that their proprietary platform based on llama antibody technology had the potential to generate agonistic antibodies that mimicked natural growth factors. Pursuing this idea, Paolo’s team succeeded to generate a set of immunoglobulins that possessed powerful anti-fibrotic and pro-regenerative activity resembling that of Hepatocyte Growth Factor (HGF), a pleiotropic protein with unique therapeutic potential. This pivotal discovery led to the foundation of AgomAb Therapeutics.



Our latest news